Growth momentum Calyxo has been raising substantial funding recently, including a $40M Series F in 2026, signaling strong investor confidence and potential for scalable production, enterprise partnerships, and expanded sales channels in the medical device market.

Strategic partnerships Recent investment from Ally Bridge Group and Janus Henderson Investors, along with ongoing support from Questa Capital, Avidity Partners, and CRG, positions Calyxo for broader distribution collaborations, co-development deals, and accelerated market access strategies.

Market leadership Recognition as one of the region’s most transformative companies, combined with a focus on advanced kidney stone treatment solutions, creates a compelling value proposition for hospital systems, clinics, and health networks seeking innovative care pathways.

Executive credibility Strong leadership with a track record of commercializing paradigm-shifting urology solutions, reinforced by board-level expertise and recent hires, supports targeted outreach to procurement teams and clinical champions in large healthcare organizations.

Product innovation Recent product developments such as the Reverse Deflection option demonstrate a user-centric approach and potential for upsell with hardware-software integrations, enabling expansion into adjacent renal care devices and related service models.